some highlights:-Solvay andShionogi/Nippon Kayaku invest more than 100 Mio Can$ in further development of cetrorelix-bringing 2005 two preclinical compounds in clinical Phase I-Licence out at least three compounds-Licence in some late stage compounds mostly in oncology
If we look at the timeline for the drugs that are in the pipeline, we get the following when it comes down to when they can get approuval:2005: Cetrotide in Japan (Will it ever come?) and Impavido2007: Neovastat (??????????? If it ever succeeds...)2009: Cetrorelix2010: perifosineSo there is a gap in 2006 and that's why AEZ wants to buy some late stage compounds. Will AEZ buy only the compunds or could it also buy the company that has these late stage compunds?
I don't find this article, where did you take this article. ??
It`s an audio interview!search google for wallstreetreporter + aeterna zentaris